Ropimax Speed Tablet 2 Milligrams (Ropinirole Hydrochloride)

Adult dose

1. Adults The optimal dose should be individualized, taking efficacy and tolerability into consideration. This medication should be taken once daily at the same time each day. It may be taken with or without food. Swallow this medication whole; do not chew, crush, or split it. 1) Initial therapy During the first week, administer this medication (extended-release tablet) 2mg once daily. Starting in the second week of treatment, increase the dose to 4mg once daily. A treatment response may occur starting at 4mg/day. 2) Maintenance therapy When administering this medication (extended-release tablet), continue treatment at the minimum dose that controls symptoms. If symptoms are inadequately controlled or not maintained with 4mg once daily, increase the dose in 2mg increments each week (or over a longer period) until the daily dose reaches 8mg. If symptoms are inadequately controlled or not maintained with 8mg once daily, increase the daily dose in increments of 2mg or 4mg at intervals of 2 weeks or longer. The maximum daily dose of this medication is 24mg. If treatment is interrupted for 1 day or longer, restarting treatment at the initial therapy dose should be considered. When ropinirole is administered concomitantly with levodopa, the levodopa dose may be reduced gradually according to the clinical response. In clinical trials, the levodopa dose was gradually reduced by up to approximately 30% in patients receiving this medication (extended-release tablet) concomitantly with levodopa. In patients with advanced Parkinson’s disease receiving concomitant levodopa, dyskinesia may occur early in treatment with this medication (extended-release tablet). In such cases, the levodopa dose should be reduced. If ropinirole is to be used as a substitute for another dopamine agonist, the other dopamine agonist should be discontinued according to its recommended method before starting ropinirole. As with other dopamine agonists, ropinirole should be discontinued by gradually reducing the daily dose over 1 week. 3) Switching from immediate-release ropinirole to this medication (extended-release tablet) Immediate-release ropinirole may be replaced with this medication (extended-release tablet) overnight. The dose of this medication should be selected according to the following dosage table, based on the patient’s total daily dose of immediate-release ropinirole. Total daily dose of immediate-release ropinirole (mg) → Total daily dose of extended-release ropinirole (mg) 0.75-2.25 → 2 3-4.5 → 4 6 → 6 7.5-9 → 8 12 → 12 15-18 → 16 21 → 20 24 → 24 After switching from immediate-release ropinirole to this medication (extended-release tablet), adjust the dose according to the treatment response. 2. Use in elderly patients Ropinirole clearance is reduced in patients aged 65 years or older; therefore, increase the dose more gradually according to the clinical response. In very elderly patients, consider increasing the dose even more gradually during the initial period of treatment. 3. Patients with renal impairment No dose adjustment is necessary because ropinirole clearance is unchanged in patients with mild or moderate renal impairment (creatinine clearance 30-50mL/min).

This medication should be used with caution in patients with severe cardiovascular disease. There is a risk of hypotension or arrhythmia when taken with antihypertensive or antiarrhythmic drugs. Patients with significant mental disorders should only use this medication when the therapeutic benefits are deemed greater than the risks. Sudden drowsiness or sleep may occur during treatment, so activities such as driving or operating machinery should be avoided. This medication should not be administered to patients with hypersensitivity to this drug, those with severe renal or liver dysfunction, pregnant or breastfeeding women, or patients with certain genetic lactose metabolism disorders. Additionally, patients with severe cardiovascular disease or allergies to specific pigments should use this medication carefully, and frequent blood pressure monitoring is advised. Common side effects may include drowsiness, dizziness, hallucinations, orthostatic hypotension, hypotension, nausea, constipation, peripheral edema, confusion, delusions, illusions, paranoia, impulse control disorders, hypersexuality, compulsive buying, binge eating, aggression, fainting, excessive daytime sleepiness, vomiting, heartburn, abdominal pain, elevated liver enzymes, lower limb edema. If abnormal symptoms occur, consult a physician. Patients and caregivers should closely monitor for psychiatric symptoms or impulsive control disorders or sudden sleep occurrences. If severe drowsiness arises during treatment, it may be necessary to reduce or discontinue the dosage. This medication should not be used in conjunction with other dopamine agonists and may interact with specific antibiotics or medications, so be sure to inform healthcare professionals before starting any new medications. Pregnant or breastfeeding women should not use this medication, and its safety and efficacy have not been established in children or adolescents under 18 years of age. In cases of overdose, dopamine-related symptoms may appear, necessitating immediate medical attention.

Hallucinations, drowsiness, movement disorders, dizziness, sudden sleep, orthostatic hypotension, hypotension, nausea, constipation, peripheral edema, hypersensitivity reactions (including urticaria, angioedema, rash, and itching), confusion, delusions, illusions, paranoid responses, impulse control disorders, hypersexuality, pathological gambling, compulsive shopping, binge eating, aggression, fainting, excessive daytime drowsiness, vomiting, heartburn, abdominal pain, liver reactions, increased liver enzymes, lower limb edema

This medication should be stored in a tightly sealed container to avoid exposure to air or moisture. It is important to maintain a storage temperature between 1 and 30 degrees Celsius.

Appearance

Pink, double-convex, rectangular film-coated sustained-release tablet, with 'KDC' embossed on one side and '2' on the other side.

Package unit

28 tablets/box [14 tablets/PTP*2]